Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Bart C. Kuenen(Vrije Universiteit Brussel), Adrian L. Harris(University of Oxford), Klaas Hoekman, Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Elisabeth Pfanner, PierFranco Conte(University of Padua), H. van der Wal- Huisman, Franco Cavalli(Institute of Social and Preventive Medicine), S. Seeber, José Baselga(Harvard University), P. Scigalla, G. Deplanque, Josep Tabernero(Deaconess Hospital)
PubMed
May 1, 2003
Cited by 127
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k